<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535221</url>
  </required_header>
  <id_info>
    <org_study_id>BCP12</org_study_id>
    <nct_id>NCT02535221</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ &amp; HER2- Breast Cancer</brief_title>
  <official_title>Randomized Trial of Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With Estrogen Receptor-Positive HER2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to prove that the efficacy of adjuvant endocrine therapy for the
      premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy
      assessed by ultrasound response rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ultrasound response rate</measure>
    <time_frame>within 2 weeks before surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pathological response rate(Miller &amp; Payne standard)</measure>
    <time_frame>with 2 weeks after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Endocrine therapy;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions：Goserelin+TAM+AI：Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions：Epirubicin+CTX+5-Fu：Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin+TAM+AI</intervention_name>
    <description>Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.</description>
    <arm_group_label>Endocrine therapy;</arm_group_label>
    <other_name>Endocrine therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin+CTX+5-Fu</intervention_name>
    <description>Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  35 years old ＜age≤55 years old, in premenopausal status(with the judgement by
             researchers when the patients are recruited) Histologically confirmed primary invasive
             breast cancer

          -  Stage: T2N0M0(cT&gt;2cm, SLNB negative), hard to proceed the breast conserving
             surgery(not feasible or may affect the appearance of breast)

          -  Histologically confirmed HR+ (ER or PR positive, and &gt;50% cell in IHC) HER2 negative
             breast cancer by pathological evaluation

          -  No other previous treatment for primary breast cancer

          -  Without other tumor or unstable complication or uncontrolled infection

          -  No contradiction for the third generation AIs, LHRHa, chemotherapy

          -  Attend the study voluntarily, sign the informed consent.

        Exclusion Criteria:

          -  Metastasis disease by pathological or radiological diagnosis

          -  the history of other tumor

          -  contradiction for the third generation AIs, LHRHa, chemotherapy

          -  Contradiction for adjuvant chemotherapy: serious cardiology or cerebral vessel
             disease, liver or kidney disfunction, blood system disease, the other situation or
             complication that are not suitable or cannot adaptable for chemotherapy

          -  Contradiction for proceeding surgery: contradiction for anesthesia, large lesion,T4,
             lymph node positive

          -  other situation not suitable for the research: psychological disease, mental disorder,
             social problem, geographic problem

          -  have been attendance in other anti-tumor treatment or other clinical trials 8) reject
             to attend the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Ouyang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Ouyang, MD</last_name>
    <email>ouyanghongtao@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital Breast Center</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Tao OUYANG</investigator_full_name>
    <investigator_title>Chairman of Breast Center of Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>Premenopausal Patients</keyword>
  <keyword>Estrogen Receptor-Positive HER2 negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

